Literature DB >> 19156490

Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease.

Caroline K Jurgens1, Lotte van de Wiel, Ad C G M van Es, Yvette M Grimbergen, Marie-Noëlle W Witjes-Ané, Jeroen van der Grond, Huub A M Middelkoop, Raymund A C Roos.   

Abstract

OBJECTIVE: To establish differences in basal ganglia and thalamic volume between preclinical carriers and non-carriers of the Huntington's disease (HD) gene and to link the volume to motor, cognitive and behavioural characteristics in carriers.
METHODS: Sixteen HD gene carriers without overt clinical motor signs and 14 non-gene carriers underwent clinical evaluation and a MRI scan. Volumes of the caudate nucleus, putamen, gobus pallidus and thalamus were measured using T1-weighted MR images. Motor, cognitive and behavioural functioning was assessed using the Unified Huntington's Disease Rating Scale (UHDRS), cognitive testing and the Beck Depression Inventory (BDI-II).
RESULTS: Volumes of the caudate nucleus, putamen and globus pallidus were significantly smaller in carriers than in non-carriers while no differences between groups were found on clinical evaluation. In gene carriers smaller globus pallidus volume was associated with more motor abnormalities. A smaller putamen volume correlated significantly with worse psychomotor function on the Symbol Digit Modalities Task and the Trail Making Test B.
CONCLUSIONS: In line with previous research we demonstrated that basal ganglia abnormalities precede overt disease manifestation of HD. Besides we showed that smaller basal ganglia volumes are related to subtle motor abnormalities and worse psychomotor performance in gene carriers without clinical diagnosis. Motor and psychomotor measures may be suitable clinical markers in future neuroprotective trials when combined with volumetric imaging.

Entities:  

Mesh:

Year:  2008        PMID: 19156490     DOI: 10.1007/s00415-008-0050-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

Review 1.  Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease.

Authors:  D Joel
Journal:  Mov Disord       Date:  2001-05       Impact factor: 10.338

2.  Behavioural complaints in participants who underwent predictive testing for Huntington's disease.

Authors:  M-N W Witjes-Ané; A H Zwinderman; A Tibben; G-J B van Ommen; R A C Roos
Journal:  J Med Genet       Date:  2002-11       Impact factor: 6.318

3.  Cognitive and motor functioning in gene carriers for Huntington's disease: a baseline study.

Authors:  Marie-Noëlle W Witjes-Ané; Maria Vegter-van der Vlis; Jeroen P P van Vugt; Jan B K Lanser; Jo Hermans; Aeilko H Zwinderman; Gert-Jan B van Ommen; Raymund A C Roos
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2003       Impact factor: 2.198

4.  Brain structure in preclinical Huntington's disease.

Authors:  Jane S Paulsen; Vince A Magnotta; Ania E Mikos; Henry L Paulson; Elizabeth Penziner; Nancy C Andreasen; Peg C Nopoulos
Journal:  Biol Psychiatry       Date:  2005-08-22       Impact factor: 13.382

5.  Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study.

Authors:  Alexander Peinemann; Sabine Schuller; Córina Pohl; Thomas Jahn; Adolf Weindl; Jan Kassubek
Journal:  J Neurol Sci       Date:  2005-09-26       Impact factor: 3.181

6.  Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study.

Authors:  Sarah A J Reading; Michael A Yassa; Arnold Bakker; Adam C Dziorny; Lisa M Gourley; Venu Yallapragada; Adam Rosenblatt; Russell L Margolis; Elizabeth H Aylward; Jason Brandt; Susumu Mori; Peter van Zijl; Susan S Bassett; Christopher A Ross
Journal:  Psychiatry Res       Date:  2005-09-30       Impact factor: 3.222

7.  Basal ganglia volume and proximity to onset in presymptomatic Huntington disease.

Authors:  E H Aylward; A M Codori; P E Barta; G D Pearlson; G J Harris; J Brandt
Journal:  Arch Neurol       Date:  1996-12

8.  Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study.

Authors:  S E Starkstein; J Brandt; F Bylsma; C Peyser; M Folstein; S E Folstein
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

9.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

10.  Profile of cognitive progression in early Huntington's disease.

Authors:  A K Ho; B J Sahakian; R G Brown; R A Barker; J R Hodges; M-N Ané; J Snowden; J Thompson; T Esmonde; R Gentry; J W Moore; T Bodner
Journal:  Neurology       Date:  2003-12-23       Impact factor: 9.910

View more
  32 in total

1.  Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation.

Authors:  D S Adnan Majid; Adam R Aron; Wesley Thompson; Sarah Sheldon; Samar Hamza; Diederick Stoffers; Dominic Holland; Jody Goldstein; Jody Corey-Bloom; Anders M Dale
Journal:  Mov Disord       Date:  2011-09-19       Impact factor: 10.338

2.  Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Authors:  J Jean Chen; David H Salat; H Diana Rosas
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

3.  Ventral striatal volume is associated with cognitive decline in older people: a population based MR-study.

Authors:  L W de Jong; Y Wang; L R White; B Yu; M A van Buchem; L J Launer
Journal:  Neurobiol Aging       Date:  2010-11-13       Impact factor: 4.673

4.  An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers.

Authors:  Anthony L Vaccarino; Karen Anderson; Beth Borowsky; Kevin Duff; Joseph Giuliano; Mark Guttman; Aileen K Ho; Michael Orth; Jane S Paulsen; Terrence Sills; Daniel P van Kammen; Kenneth R Evans
Journal:  Mov Disord       Date:  2011-03-02       Impact factor: 10.338

5.  Regional atrophy associated with cognitive and motor function in prodromal Huntington disease.

Authors:  Elizabeth H Aylward; Deborah L Harrington; James A Mills; Peggy C Nopoulos; Christopher A Ross; Jeffrey D Long; Dawei Liu; Holly K Westervelt; Jane S Paulsen
Journal:  J Huntingtons Dis       Date:  2013

6.  Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease.

Authors:  Meike Herben-Dekker; Joost C H van Oostrom; Raymund A C Roos; Caroline K Jurgens; Marie-Noëlle W Witjes-Ané; Hubertus P H Kremer; Klaus L Leenders; Jacoba M Spikman
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

7.  Social anhedonia in major depressive disorder: a symptom-specific neuroimaging approach.

Authors:  Verena Enneking; Pia Krüssel; Dario Zaremba; Katharina Dohm; Dominik Grotegerd; Katharina Förster; Susanne Meinert; Christian Bürger; Fanni Dzvonyar; Elisabeth J Leehr; Joscha Böhnlein; Jonathan Repple; Nils Opel; Nils R Winter; Tim Hahn; Ronny Redlich; Udo Dannlowski
Journal:  Neuropsychopharmacology       Date:  2018-11-27       Impact factor: 7.853

8.  Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.

Authors:  Lin Chen; Jun Hua; Christopher A Ross; Shuhui Cai; Peter C M van Zijl; Xu Li
Journal:  J Neurosci Res       Date:  2018-11-29       Impact factor: 4.164

9.  MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease.

Authors:  Caroline K Jurgens; Radu Jasinschi; Ahmet Ekin; Marie-Noëlle W Witjes-Ané; Huub Middelkoop; Jeroen van der Grond; Raymund A C Roos
Journal:  PLoS Curr       Date:  2010-09-08

10.  Magnetization transfer imaging in 'premanifest' Huntington's disease.

Authors:  Caroline K Jurgens; Reineke Bos; Jasper Luyendijk; Marie-Noëlle W Witjes-Ané; Jeroen van der Grond; Huub A M Middelkoop; Raymund A C Roos
Journal:  J Neurol       Date:  2009-10-13       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.